Taurine

Clinical Summary

Conditionally essential sulfur-containing amino acid. Synthesized endogenously from cysteine/methionine via CDO1 + CSAD (Vitamin-B6 cofactor), with vegetarian/vegan plasma levels 20–30% lower than omnivores. Functions as osmolyte, calcium-channel modulator, weak GABA-A/glycine partial agonist, mitochondrial tRNA-modification substrate (via TauT/SLC6A6 — also localizes to mitochondria per Li 2026 PMID 41652173), and taurocholate precursor for bile-acid conjugation.

The clinically replicated value sits in cardiometabolic risk-factor reduction: modest BP lowering (SBP −4 mmHg, DBP −1.5 mmHg across 34 RCTs), glycemic improvement (HbA1c −0.2%, FBG −6 mg/dL), lipid improvement (TG, TC, LDL-C all modestly reduced), and symptomatic benefit in heart failure within Japanese guideline-directed practice. Ergogenic effect for endurance is real but small (g=0.25) and mostly expressed in combination with caffeine. The 2023 Singh Science "taurine deficiency drives aging" hypothesis has NOT replicated in humans: Fernandez/de Cabo 2025, Marcangeli 2025, and Kim 2026 all refuted the core claim. The only unequivocal single-gene disease indication is SLC6A6 biallelic loss-of-function → early-onset retinal dystrophy (PMID 41343195).

Safety profile at 1–3 g/d is excellent (0 suspect-only FAERS reports across 1,383 records). Two genuine concerns emerged 2024–2026: Sharma Nature 2025 showed taurine from the bone-marrow niche feeds acute myeloid leukemia stem cells via TAUT→mTOR→glycolysis, making active myeloid malignancy a contraindication; Pei 2026 showed high-dose taurine (3 g/kg/d) exacerbates alcohol-associated liver disease in mice via H2S-producing bacteria, arguing against high-dose use in heavy drinkers. Reader benefit is highest in cardiometabolic risk, heart failure under cardiologist care (Japan), MELAS/RP for genetic indications, and endurance athletics.

Indications & Evidence

Reading this table: Stars = evidence volume. Type = causal relationship class. BH = Bradford Hill criteria met (/9). Safety = FAERS/trial signals for THIS indication.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | FA=Folk/anecdotal | NE=No evidence BH: 7–9 strong | 5–6 moderate | 3–4 weak | 1–2 speculative | 0 none Safety: -- no signals | MON monitorable AEs | WARN FAERS/trial signal | AVOID contraindicated

Hard rule: Star rating ≤ causal taxonomy ceiling. The 2026 retraction of a Japanese taurine HF trial (PMID 41943494) was integrated into the HF row star cap.

Prescribing

Dosing Table

Upper tolerable limit: No official UL. Shao & Hathcock 2008 Observed Safe Level = 3 g/d. Doses 6–10 g/d used in RCTs without serious AEs. Avoid 3+ g/kg/d (rodent ALD harm PMID 41809269 translated to ~200 g for humans — unreachable orally but relevant as a ceiling principle).

Formulation Table

L-Taurine free-form is the correct default. Doses above 3 g/d warrant splitting (twice or three times daily) to stay within the TauT absorption window (>90% at ≤3 g/dose, declining to 60–75% at 6 g). Powder and capsule are bioequivalent; powder offers 40–50% cost savings.

Condition-Specific Protocols

Congestive Heart Failure (Japan Class IIb adjunct)

Evidence: 3/5 | Key PMIDs 39148075, 3888464, 40159241 (JCS/JHFS 2025 guideline). PMID 41943494 retraction (2026) affects part of the older Japanese evidence base.

Phase 1 — Initiation (Weeks 1–2)

• 1 g TID with meals. Monitor: BP, HR, symptom diary.
• Confirm background GDMT (ARNi, beta-blocker, MRA, SGLT2i) is fully optimized BEFORE adding taurine. Taurine is an adjunct, never monotherapy.

Phase 2 — Therapeutic (Weeks 3–12)

• 2 g TID (6 g/d total) with meals. Monitor weekly BP/HR; NYHA class at 4 and 12 weeks; LVEF at 12 weeks if echo scheduled.
• Expected outcomes (meta-analysis pooled): HR −3.6 bpm, SBP −4 mmHg, NYHA −0.4 class, LVEF +5% at 8–12 weeks.

Phase 3 — Maintenance (Week 12+)

• 1.5–2 g BID ongoing if symptomatic/functional improvement documented. Reassess every 6 months. Discontinue if no symptomatic benefit by week 16.

Drug Interaction Timing: Monitor SBP if on ACEi/ARB/ARNi/beta-blocker — additive effect can cause symptomatic hypotension. Expected Outcomes: NYHA improvement by 4–8 weeks; echo LVEF change by 12 weeks. Stop/Reassess Criteria: SBP <95 mmHg symptomatic; worsening renal function; addition of new anti-arrhythmic.

MELAS Stroke-Like Episode Prevention (Japan PMDA Rx indication)

Evidence: 4/5 | Key PMID 29666206 (Ohsawa KN01 Phase 3, N=10, open-label)

Phase 1 — Titration (Weeks 1–4)

• Start 3 g/d split TID. Titrate by 3 g/d each week up to 9–12 g/d as tolerated.

Phase 2 — Maintenance

• 9–12 g/d divided TID–QID long-term. Primary endpoint: reduction in annual stroke-like episode rate (baseline 2.22 → 0.72/yr in trial).
• Monitor: MRI for new stroke-like lesions every 6–12 mo; lactate/pyruvate if metabolic workup done; GI tolerance (major limiter).

Stop/Reassess: Intolerable GI symptoms; new drug interactions; stroke-like episode frequency unchanged after 12 mo.

Caveat: Approval rests on one open-label N=10 trial. Western centers outside Japan typically use 3–9 g/d off-label as a mitochondrial-disease adjunct. The 2026 Yoshida response letter (PMID 41945256) acknowledges ongoing methodological critique.

Retinitis Pigmentosa — SLC6A6 LOF subtype (Japan Rx)

Evidence: 3/5 | Key PMID 41343195 (Ullah 2026 JAMA Ophthalmol)

Eligibility: Biallelic pathogenic SLC6A6 variants confirmed by genetic testing. Plasma taurine ~38 μmol/L below healthy controls. Do NOT apply this protocol to generic RP without SLC6A6 genotyping.

Protocol: 500 mg/d oral taurine long-term. Monitor: plasma taurine (aim 60–100 μmol/L); ERG and visual fields annually.

Rationale: Replaces a transporter-driven retinal taurine deficit. Heterozygote carriers do NOT require supplementation.

Safety

Interactions Table

No CYP450 interactions. Does not affect anticoagulant metabolism.

Contraindications

• Active acute myeloid leukemia, MDS, or other aggressive myeloid malignancy (Sharma 2025 PMID 40369079 — bone-marrow niche taurine feeds LSC glycolysis via TAUT/mTOR; TAUT loss impairs AML progression)
• Severe alcohol use disorder with active alcoholic liver disease for doses >3 g/d (Pei 2026 PMID 41809269; low-dose appears acceptable)
• Lithium therapy unless serum levels monitored
• Severe symptomatic hypotension (SBP <90 mmHg)
• Pregnancy / lactation at supraphysiologic doses — no safety RCTs; dietary intake is essential for fetal development but supplementation beyond 500 mg/d lacks safety data
• Pediatric use outside NICU/medical supervision — safety not established for chronic supplementation in children

Caveat on AML contraindication: the Sharma paper describes paracrine feeding of established LSCs, not de-novo oncogenesis from supplementation. Prophylactic avoidance for individuals with high AML risk (heavy benzene exposure, family history, prior chemo-induced MDS/AML) is cautious rather than evidence-grounded — flag and discuss with oncologist.

Adverse Effects

Ranked by frequency across RCTs (typical 1.5–3 g/d for 8–12 weeks):

• Mild GI upset — 2–5% at doses >3 g/d; transient
• Nausea — 1–3%, worse on empty stomach at high single doses
• Loose stools / diarrhea — primarily >6 g/d, osmotic mechanism
• Paradoxical evening activation / vivid dreams — community-reported, not RCT-quantified; mechanism possibly glutamate rebound
• Headache — rare, may track BP reduction
• Dizziness — rare, BP-related in hypertensives

No hepatotoxicity, nephrotoxicity, or hematologic toxicity at supplementation doses. No dependence or withdrawal.

FAERS Signal Table

Zero FAERS reports with taurine as suspect-only across 1,383 cumulative records. The seizure cluster is driven by trial populations with intrinsic seizure disorders and by co-administered anticonvulsants. This is the cleanest supplement FAERS profile in the library — consistent with the OSL of 3 g/d and >12-month RCT safety across 30+ trials. Pattern fits "FAERS supplement noise" (concomitant inflation via TPN and combination products).

Monitoring Table

Special Populations

Renal Impairment

Hepatic Impairment

Alcohol-associated liver disease exception: Pei 2026 (PMID 41809269) showed dose-inversion in mice — high-dose (3 g/kg) taurine EXACERBATED ALD via H2S-producing gut bacteria, while low-dose (0.2 g/kg) was protective. In humans with heavy alcohol intake, cap taurine at 1 g/d or avoid.

Pregnancy / Lactation

No controlled human RCTs. Taurine is conditionally essential in neonates (fetal brain, retina, bile-acid metabolism); infant formulas are fortified to match breast milk (30–60 mg/L). Dietary maternal intake from meat/fish is sufficient and safe. Supplementation >500 mg/d during pregnancy lacks safety data — avoid except under obstetrics/MFM supervision.

Synergies & Stacking

Antagonism: Beta-Alanine at chronic >3 g/d depletes muscle taurine via shared TauT transporter — the only clinically meaningful taurine antagonism.

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

Community & Anecdotal Evidence

Disclaimer: Real-world reports from online communities. None constitutes clinical evidence. N-sizes approximate. Selection and recall bias inherent. Presented for completeness.

Dominant Sentiment

Mixed-positive across ~thousands of reports, historically anchored by r/Nootropics, Longecity taurine threads, Mayo Clinic Connect palpitation forum, Tinnitus Talk, and r/POTS. Enthusiasm peaked 2023–2024 post-Singh Science paper and deflated through mid-2025 as the Fernandez/de Cabo counter-paper propagated.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• Energy drink marketing blur: Red Bull / Monster / Rockstar promote taurine as "energizing" when it is GABAergic/anxiolytic. Industry benefits from mislabeling the mechanism.
• Taisho Pharmaceutical conflict: Manufactures both the Japanese Rx taurine AND Lipovitan-D. Almost every Japanese taurine RCT from 1985 onward (Azuma CHF series, Kuriyama, Ohsawa MELAS KN01, Sato 2024 physical-fitness cohort PMID 38571751) carries Taisho funding or Taisho-employee authorship. The PMID 41943494 retraction in 2026 affects part of this corpus.
• Influencer hype asymmetry: Rhonda Patrick heavily promoted Singh 2023 via FoundMyFitness; did not comparably cover Fernandez/de Cabo 2025 refutation. Peter Attia remained cautious. Sinclair added taurine 2023 then dropped it publicly June 2025. Bryan Johnson's Blueprint Longevity Mix retains taurine 1,500 mg/serving — direct commercial conflict.
• Supplement industry SEO: Nootropics Expert, Longecity vendor cross-posts, BioHackers Lab, NOVOS affiliate structures. "Research summaries" are ranking-optimized, not evidence-weighted.
• Lipovitan-D safety halo fallacy: 60+ years of Japanese Lipovitan use is cited as safety proof, but a 100-mL serving delivers ~1 g taurine + 50 mg caffeine + B vitamins — NOT equivalent to 3–6 g/d isolated supplementation.
• Leukemia downplaying (2025–2026): Trade press framed Sharma 2025 as "only about existing cancer cells." The mechanism (TAUT-driven glycolysis in AML niche) is narrower than a general oncogenic claim BUT justifies caution for individuals with active myeloid malignancy or chemo-induced MDS history.

Folk vs Clinical Reality Check

Folk consensus aligns with clinical evidence for anxiolysis at 0.5–2 g (small RCT + community agree), sleep quality with magnesium stacking (mechanism + effect plausible), modest BP reduction (RCT-backed), and exercise-recovery modulation (meta-analysis small but positive). Folk OVERSHOOTS clinical for longevity at 3–6 g/d (human evidence actively collapsing 2025–2026), tinnitus (animal-only RCT support), eye floaters (anecdote-only), hair/skin/nails (essentially no signal), libido/ED (aged-rat data). Folk UNDERSHOOTS clinical concern for SLC6A6/TAUT-driven AML risk (Sharma 2025 underrepresented in biohacker discourse), high-dose taurine + heavy alcohol interaction, lithium clearance, and bipolar destabilization risk at high dose.

One area where folk pre-empted clinicians: PVC/palpitation benefit at 2–3 g/d. Decades of Mayo Clinic Connect and Reddit testimonials preceded any formal trial — the patient-reported-outcome signal has been strong and consistent even without a dedicated RCT.

Deep Dive: Mechanisms & Research

Transporter biology (2025–2026 structural explosion):

• Four cryo-EM structures of TauT/SLC6A6 published 2025–2026 (PMIDs 40601627, 40615403, 41269860, 41857056) resolving substrate recognition, cholesterol-mediated dimerization, and inhibitor binding.
• Li 2026 Nature Metabolism (PMID 41652173) identified mitochondrial localization of SLC6A6, separate from the plasma-membrane pool. PKA regulates plasma-membrane targeting; NFAT5 regulates mitochondrial pool. Taurine at the mitochondrial face supports mt-tRNA modification essential for mitochondrial translation — this is the mechanism upstream of the Japanese MELAS indication and of the Sharma AML dependency.

Core physiological roles:

1. Osmoregulation (cell volume; brain, heart, retina)
2. Ca²⁺-channel modulation (L-type cardiac; antiarrhythmic mechanism)
3. Membrane stabilization
4. Bile acid conjugation → taurocholate/taurodeoxycholate (FXR/TGR5 signaling)
5. Mitochondrial protein synthesis via mt-tRNA taurine-modification
6. Weak partial agonism at GABA-A and glycine receptors (anxiolytic mechanism)
7. Antioxidant: direct HOCl scavenging → taurine chloramine; Nrf2 induction; glutathione preservation

Aging controversy trajectory (2023 → 2026):

• Singh 2023 Science (PMID 37289866): Taurine decline with age across species; supplementation extends mouse lifespan +10–12% and improves primate biomarkers.
• Fernandez & de Cabo 2025 Science (PMID 40472098): BLSA longitudinal cohort (N=742 humans, 3–5 draws/7.8 y) + rhesus + mouse — plasma taurine is STABLE or INCREASES with age; inter-individual variability dwarfs age effect. Taurine is NOT a useful aging biomarker.
• Marcangeli 2025 Aging Cell (PMID 41061678): N=137 men 20–93 y. No association of plasma taurine with age, muscle mass, strength, physical performance, or mitochondrial function.
• Jankowski 2025 Cell Metab (PMID 41106390): "Many amino acids (but notably not taurine) change with age" in aged-mouse metabolomics.
• Kim 2026 NPJ Aging (PMID 41667480): Non-monotonic taurine/frailty relationship — robust > frail > prefrail; frailty, not chronological age, is the variable.
• Monti 2026 GeroScience (PMID 41888502): New England Centenarian Study — bile acids (CDCA, LCA), not taurine, are the strongest survival-associated metabolites.
• NCT06613542 Munich aging RCT: 4 g/d × 6 mo in 90 adults aged 55–75, DNA methylation primary endpoint. Completed 2025-11-13; results pending publication — most important human readout remaining.

Oncology signal (emerging):

• Sharma 2025 Nature (PMID 40369079): Osteolineage cells in bone marrow produce taurine via CDO1 → export → AML stem cells import via TAUT → RAG-GTP → mTOR → glycolysis → leukemia progression. TAUT knockout and CDO1 knockdown impair AML in vivo. Venetoclax synergy.
• Li 2026 Nat Metab (PMID 41652173): SLC6A6 mitochondrial import sustains tumour growth across multiple cancer types.
• Cai 2026 breast cancer (PMID 41597281): Taurine-SLC6A6 axis accelerates G1/S; high SLC6A6 → poor prognosis.
• Sinha 2024 CRC meta-analysis (PMID 39632512): Taurine elevated in CRC patient blood; diagnostic metabolite; H2S-producing gut bacteria hypothesis for mechanism.
• Counter-signals: Liu 2026 (gastric metaplasia suppression PMID 41695925), Farage 2026 (Nrf2/NF-κB protection PMID 41702182), Rao 2026 (ASL/urea cycle PMID 41708583) — context-dependent duality confirmed.

Net: taurine is a context-dependent tumor-metabolism modulator. Healthy supplementation in non-cancer populations has unclear cancer risk. In active myeloid malignancy, avoid. In high-risk myeloid populations (heavy benzene exposure, chemo-induced MDS, Li-Fraumeni), discuss with oncology.

Clinical Trials (from BioMCP / ClinicalTrials.gov)

Total ClinicalTrials.gov: 55 by condition / 141 by intervention (many combination products). See BioMCP for full list.

Regulatory Status

• FDA: GRAS Notice 586 acknowledged; permitted as infant formula ingredient (voluntary fortification, ~30–60 mg/L match to breast milk); component of approved parenteral nutrition amino-acid mixtures (Premasol, Aminosyn-PF, Trophamine); no standalone Rx monotherapy approval.
• EFSA: 2009 Scientific Opinion (ANS Panel) — safe at energy-drink exposure levels; NOAEL 1,000 mg/kg bw/d in rat; Observed Safe Level 3 g/d in humans. 2025 EFSA feed-additive reauthorization for Canidae/Felidae/fish plus new authorization up to 0.2% in poultry/porcine feed (PMID 40708713).
• Japan PMDA: Rx-approved as Taurine Powder 98% "Taisho" for (1) MELAS stroke-like episode prevention (9–12 g/d, 2013 approval), (2) congestive heart failure (3–6 g/d, 1985 approval), (3) chronic liver dysfunction adjunct, (4) retinitis pigmentosa (500 mg/d).
• Health Canada: Permitted Natural Health Product ingredient. Energy drinks: caffeine capped at 180 mg/serving; taurine not separately capped. 2026 new "Supplemented with" labeling mandate active.
• TGA Australia / FSANZ: Permitted; energy-drink max 3,000 mg/L.
• WADA / ITA: NOT on 2026 Prohibited List; not monitored. Amino-acid category outside GlobalDRO scope. Contamination (third-party adulteration) is the only doping concern.
• EU energy drinks: Permitted; country-level restrictions on sales to minors (Latvia, Lithuania, Poland, Hungary) exist but no ingredient-level ban. 2026 European Parliament briefing (PE 779236) recommends EU-wide minor-sale restriction, not ingredient ban.

Ataraxia Verdict (as of 2026-04-17)

Evidence Classification (Mode 5)

Hype Check (Mode 1)

• Appeal to nature ("natural amino acid so safe") — overrides Sharma 2025 AML mechanism
• Hasty generalization from mouse longevity to human longevity (Singh 2023) — replication has failed
• Appeal to authority via "approved in Japan for heart failure" without acknowledging Japanese regulatory standards differ, one 2026 Japanese HF trial was retracted, and Western guidelines do not endorse
• Cherry-picking Singh positive data over Fernandez/Marcangeli refutations in supplement marketing
• False equivalence Lipovitan-D 1 g/d safety (60 years Japanese data) claimed as proof of 3–6 g/d supplementation safety
• Anchoring bias to the 2023 Science headline; biohackers have been slow to integrate 2025–2026 counter-evidence

Evidence Gaps

• Whether isolated long-term supplementation at 3–6 g/d has net aging benefit or net cancer-pathway risk — NCT06613542 readout pending
• Human RCTs of dose-inversion: does high-dose taurine interact negatively with gut microbiome in heavy drinkers (extrapolate Pei 2026 PMID 41809269)?
• Whether MELAS indication replicates in placebo-controlled trials outside Japan
• Women and peri/postmenopausal populations (Seghieri & Franconi 2025 — substantial sex-gender gap)
• Pregnancy supplementation safety >500 mg/d
• Whether SLC6A6 common polymorphisms alter clinical response
• Long-COVID: single trial ongoing, too early to judge
• Chronic AML/MDS risk in long-term high-dose supplementation (theoretical; paracrine niche mechanism may or may not translate to de-novo risk)

Bias Flags (Mode 4)

• First principles: Endogenous synthesis + adequate dietary intake from meat/fish/shellfish renders supplementation redundant in most omnivores. Vegetarians/vegans have 20–30% lower levels and a theoretical rationale. Supplementing "for longevity" at 3–6 g/d has collapsed as a first-principles argument.
• What survives scrutiny: Modest cardiometabolic benefit at 1.5–3 g/d for people with relevant risk factors; MELAS/RP genetic indications; endurance adjunct with caffeine; liver transplant adjunctive.
• What doesn't survive: Anti-aging, cognitive enhancement, weight loss, testosterone, hair growth.
• Cui bono: Supplement industry (Thorne, NOVOS, Blueprint, Life Extension) benefits most from the longevity framing. Taisho Pharmaceutical benefits from the Japanese Rx + OTC dual presence. Red Bull/Monster benefit from misattributing "energizing" to taurine. Pharma has minimal counter-interest. Academic longevity researchers (Yadav lab; Patrick/Sinclair-adjacent) benefit from hype cycles.
• Supply chain: Synthetic manufacturing (low heavy-metal risk). Quality markers: USP/NSF, ≥99% purity, CoA available, no proprietary blends.

Manipulation Flags (Mode 2)

• Industry marketing: Red Bull/Monster/Rockstar energy-drink framing of taurine as "energizing" contradicts its GABAergic/anxiolytic mechanism. Multiple "longevity taurine" SKUs launched 2023–2024 built on Singh; most have not updated copy despite 2025–2026 refutations. Blueprint/Bryan Johnson's Longevity Mix retains 1,500 mg/serving with commercial conflict.
• Influencer economics: Rhonda Patrick FoundMyFitness heavily promoted Singh 2023; uneven coverage of Fernandez/Marcangeli refutations. Huberman Lab neutral. Attia cautious from the start. Sinclair publicly adopted taurine 2023 and dropped it June 2025 (Diamandis interview). Bryan Johnson retains commercial commitment.
• Counter-narrative manipulation: Trade press downplayed Sharma 2025 leukemia paper. Japanese pharma media under-emphasizes Western aging refutations.
• Cui bono summary: If you supplement taurine, supplement industry + Taisho + Blueprint win; if you don't, no one in particular loses. The incentive structure is asymmetric toward hype.
• Red team highlight: The ONE angle deserving highest concern is the Sharma 2025 mechanism cross-referenced with Li 2026 mitochondrial SLC6A6 — if SLC6A6 is a general tumor-metabolism dependency, then supplementing at supraphysiologic levels in populations with undetected myeloid clonal hematopoiesis (CHIP) could theoretically accelerate progression. This is speculative but worth flagging for older adults and chemo-survivors.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 5/10 — modest but replicated cardiometabolic benefit, genuine single-gene Rx indications (MELAS, RP), small ergogenic effect, excellent safety at 1–3 g/d. Collapsing longevity claim and emerging cancer-context caution temper the score. Endogenous synthesis + dietary availability reduce the "must have" character.
• Opportunity cost: Very low — cheap (~$6–10/month for 2 g/d), low complexity, no meaningful drug interactions in most users.
• Verdict: CONDITIONAL — warranted when specific indications are present; not a universal "add to everyone" supplement.
• Conditions warranting use:
  • Documented prehypertension/hypertension or MetS/T2DM seeking adjunctive risk-factor reduction (1.5–3 g/d, 12-wk trial, track BP + HbA1c)
  • Heart failure under cardiologist care where GDMT is optimized and Japanese-style adjunctive therapy is considered (3–6 g/d)
  • Genetic diagnosis of MELAS (m.3243A>G) or SLC6A6 biallelic LOF — Rx indication per Japanese practice
  • Endurance athletes seeking marginal ergogenic effect, paired with caffeine, pre-competition
  • Vegan/vegetarian with documented low plasma taurine (<40 μmol/L) and cardiovascular risk
  • Post-liver-transplant adjunctive (2 g/d × 30 d, per Mottaghi 2026)
  • Long-term biohacker use ≤1.5 g/d with bloodwork tracking (BP, HbA1c, liver enzymes)
• Conditions warranting avoidance/caution:
  • Active AML, MDS, CML, or aggressive myeloid malignancy (Sharma 2025 mechanism)
  • Chemo-induced MDS history, heavy benzene exposure, known CHIP with myeloid trajectory
  • Heavy alcohol use with alcoholic liver disease (dose-inversion harm signal, Pei 2026)
  • Lithium therapy without level monitoring
  • Pregnancy/lactation at >500 mg/d supplementation
  • Bipolar patients considering high-dose — community reports of destabilization

Bottom Line

Taurine is a genuinely replicated but modest cardiometabolic compound with narrow Rx-worthy genetic indications and a recently-collapsed longevity narrative. Use it if the specific indication fits. Do not buy the longevity story without waiting for the Munich NCT06613542 readout and subsequent human replication. Respect the Sharma 2025 contraindication in active myeloid malignancy and the Pei 2026 dose-inversion caution in heavy alcohol use. Food-first (seafood, dark poultry meat) covers ~75% of the cardiometabolic benefit for most omnivores; supplementation is additive, not foundational.

Practical Notes

Brands & Product Selection

Quality markers: USP Verified, NSF Certified, or ConsumerLab-approved; ≥99% purity pharmaceutical/USP grade; CoA available on request; no proprietary blends; L-Taurine or simply "Taurine" on label (the L-form is the only naturally occurring form).

Red flags: proprietary "cardiovascular support" blends with undisclosed taurine dose; "fat burner" formulations with excessive caffeine; testosterone-boosting marketing claims (unsupported); suspiciously cheap bulk powder from unverified sources.

Budget-friendly: BulkSupplements (USP-grade powder, third-party tested), NOW Foods (NSF capsules). Premium: Thorne Research (NSF for Sport), Pure Encapsulations, Life Extension. Athletic: Transparent Labs, Jarrow. International: Myprotein, Bulk (UK). Magnesium-taurate bonded form: Cardiovascular Research / Ecological Formulas.

Heavy-metal risk: low — taurine is synthesized, not plant/animal-extracted.

Storage & Handling

Room temperature 15–25 °C; store in original container; moisture causes powder clumping (silica packets help); shelf life 2–3 y unopened, 18–24 mo after opening. Heat- and pH-stable — can be added to hot beverages.

Palatability & Compliance

Slightly bitter/sour; mild versus most amino acids. Highly soluble (500 mg/mL at room temp). Mixes cleanly with water, juice, smoothies, coffee, tea, pre-workout drinks, protein shakes. Capsules eliminate taste. Split-dose (morning + evening) improves both GI tolerance and therapeutic blood levels for 3+ g/d protocols. The #1 determinant of efficacy is consistency — pair with an existing habit (morning coffee, pre-workout, bedtime magnesium).

Exercise & Circadian Timing

Pre-exercise 60–120 min pre at 1–6 g for acute ergogenic (aligns with plasma peak 1–2 h). Split dosing for cardiometabolic (morning + evening) gives more stable plasma. Evening dose generally well-tolerated given weak GABA-A effect; ~10–15% of community users report paradoxical activation at high evening doses, in which case shift all dosing to AM/afternoon.

Reference Ranges (Expected Biomarker Changes)

Cost

Bulk powder is the clear cost winner. No proven clinical advantage to N-acetyl or proprietary forms.

What We Don't Know

• Whether 3–6 g/d taurine supplementation has net longevity effect in humans (NCT06613542 pending; Fernandez/Marcangeli/Kim already refute core Singh premise)
• Whether the Sharma 2025 AML paracrine mechanism translates to increased de-novo cancer risk in long-term supplementing populations
• Whether MELAS efficacy replicates in Western placebo-controlled trials (Japan PMDA basis is open-label N=10)
• Long-COVID efficacy (NCT06721949 recruiting)
• Effect in peri/postmenopausal women (severe research gap)
• Pregnancy supplementation safety at >500 mg/d
• Whether SLC6A6 common polymorphisms meaningfully alter clinical response to supplementation
• Whether the dose-inversion observed in mouse ALD (Pei 2026) occurs in humans with chronic heavy alcohol use
• Whether chronic long-term (>5 y) supplementation at 3+ g/d carries any cumulative signal
• Head-to-head comparative efficacy vs CoQ10, L-carnitine, creatine in modern protocols
• Optimal form in renal impairment
• Reliable plasma taurine testing standards outside research settings

References

Systematic Reviews & Meta-Analyses

1. Nie et al. (2025) Nutr Rev — 34 RCTs cardiometabolic. FBG −5.90, HbA1c −0.21%, LDL −5.1, SBP −4.38, DBP −2.54 mmHg; 1.5–3 g/d optimal. PMID: 41275513
2. Tzang et al. (2024) Nutr J — 20 RCTs, N=808. HR −3.58, SBP −4.00, DBP −1.44, LVEF +4.98%, NYHA −0.4 class. PMID: 39148075
3. Tzang et al. (2024) Nutr Diabetes — 25 RCTs, N=1024 metabolic syndrome. SBP −4.00, DBP −1.51 mmHg; FBG and TG significant. PMID: 38755142
4. Sun & Wang (2024) Nutrients — 9 RCTs long-term overweight/obese. 3 g/d > <3 g/d; HbA1c and HOMA-IR in obese subgroup only. PMID: 39796489
5. Wang et al. (2026) BMC Infect Dis — 27 trials long-COVID-relevant. 3 g/d sweet spot; ↓HbA1c, insulin, CRP, TNF-α, IL-6. PMID: 41803812
6. Cao et al. (2025) cognition MA — 7 RCTs, N=402. No cognitive benefit from taurine alone. PMID: 40320621
7. Deng et al. (2025) Scand J Med Sci Sports — 23 RCTs acute exercise, g=0.25, GRADE low. PMID: 40852891
8. Deng et al. (2025) J ISSN — Network MA caffeine ± taurine. CAF+TAU synergy g=0.46 anaerobic, g=0.75 reaction time. PMID: 41032459
9. Waldron et al. (2018) Sports Medicine — endurance exercise +1.7%. PMID: 29546641
10. Moore & Young (2026) Foods — 8 RCTs N=244, SCAAs cognition; minor/inconsistent. PMID: 41750826
11. Malek Mahdavi et al. (2026) Amino Acids — SLE SR, 6 preclinical, 0 qualifying clinical. PMID: 41874670

Landmark RCTs & Human Trials

12. Ohsawa et al. (2019) J Neurol Neurosurg Psychiatry — MELAS KN01 Phase 3, N=10, 9–12 g/d × 52 wk. Annual relapse 2.22 → 0.72 (p=0.001). Basis for Japan PMDA approval. PMID: 29666206
13. Schwarzer et al. (2018) — Portal hypertension RCT, N=30, 6 g/d × 28 d; HVPG −12% vs +7% placebo (p=0.030). PMID: 29105115
14. Mottaghi et al. (2026) Clin Nutr ESPEN — Liver transplant RCT, N=169, 2 g/d × 30 d; ↓AST, bilirubin, INR, mortality. PMID: 41605371
15. DELAY-CKD (2026) — NAC 150 mg + taurine 500 mg × 180 d, N=100; microalbumin −34%, cystatin-C −21%. PMID: 41994792
16. Sun et al. (2016) — Chinese prehypertension RCT, N=120, 1.6 g/d × 12 wk; SBP −7.2, DBP −4.7 mmHg. NCT01816698
17. Azuma et al. (1985) Clin Cardiol — Japanese CHF double-blind crossover. PMID: 3888464
18. RETRACTION J Diet Suppl (2026) — "Taurine supplementation improves functional capacity... in heart failure" retracted. PMID: 41943494

Aging Controversy (Replication Crisis)

19. Singh et al. (2023) Science — "Taurine deficiency as a driver of aging"; mouse +10–12% lifespan, primate biomarker improvement. PMID: 37289866 (not retracted but substantially contradicted)
20. Fernandez & de Cabo (2025) Science — BLSA longitudinal N=742 humans + rhesus + mouse: plasma taurine STABLE or INCREASES with age; NOT an aging biomarker. PMID: 40472098
21. Marcangeli et al. (2025) Aging Cell — N=137 men 20–93 y; no association of plasma taurine with age, muscle, performance, mitochondrial function. PMID: 41061678
22. Jankowski et al. (2025) Cell Metab — Aged-mouse metabolomics: "notably not taurine" changes with age. PMID: 41106390
23. Kim et al. (2026) NPJ Aging — Non-monotonic taurine/frailty. PMID: 41667480
24. Monti et al. (2026) GeroScience — NECS centenarian study; bile acids > taurine for survival. PMID: 41888502
25. McGaunn & Baur (2023) Science commentary on Singh paper. PMID: 37289872

Oncology Mechanism Signal

26. Sharma, Rodems, Bajaj et al. (2025) Nature — Taurine from bone marrow niche drives AML via TAUT/mTOR/glycolysis; venetoclax synergy. PMID: 40369079
27. Li et al. (2026) Nat Metab — SLC6A6 mitochondrial localization sustains tumour growth. PMID: 41652173
28. Cai et al. (2026) — Taurine-SLC6A6 in breast cancer. PMID: 41597281
29. Sinha et al. (2024) Cancer Med — Taurine as CRC diagnostic metabolite. PMID: 39632512
30. Liang et al. (2025) J Adv Res — Serum taurine in lung cancer immune escape. PMID: 39243941
31. Huang et al. (2025) Metabolites — Taurine facilitates HCC via bile acid. PMID: 41590614

Liver Context (Dose Duality)

32. Pei et al. (2026) eGastroenterology — High-dose taurine (3 g/kg) EXACERBATES alcohol liver disease; low-dose protective. PMID: 41809269
33. Zhang et al. (2026) Food Funct — Chinese cohort N=16,699; dietary taurine NOT associated with MASLD. PMID: 41738963
34. Meng & Gao (2025) Cell Commun Signal — MASLD gut-liver axis review. PMID: 41094516

Mechanism & Transporter Biology

35. Wang et al. (2025) PNAS — Mouse + human TauT cryo-EM structures. PMID: 40601627
36. Zhang et al. (2025) Nat Commun — TauT dimerization with cholesterol. PMID: 40615403
37. Lu et al. (2025) Cell Rep — 5 TauT structures with substrates/inhibitors. PMID: 41269860
38. Qi et al. (2026) Nat Commun — TauT + P4S inhibitor complex. PMID: 41857056
39. Jong, Sandal & Schaffer (2021) Molecules — Mitochondrial health review. PMID: 34443494
40. Ullah et al. (2026) JAMA Ophthalmol — Biallelic SLC6A6 variants → Leber congenital amaurosis / early-onset retinal dystrophy. PMID: 41343195

Safety & Pharmacokinetics

41. Ghandforoush-Sattari et al. (2010) — PK in healthy adults, N=12; bioavailability >90%, t½ 1–2 h. PMID: 22331997
42. Shao & Hathcock (2008) — Risk assessment; Observed Safe Level 3 g/d.
43. Ghamlouch et al. (2025) Cardiovasc Toxicol — Energy drink cardiotoxicity SR. PMID: 41266869
44. Dobrek (2025) Nutrients — Energy drink AE review. PMID: 40806020
45. Wolk et al. (2012) — Energy drink toxicity; taurine not implicated. PMID: 22426157
46. Jagim et al. (2023) ISSN position on energy drinks. PMID: 36862943
47. Ding et al. (2020) — Pediatric tic trial safety, up to 4 g/d. PMID: 31618495

Guidelines & Regulatory

48. Tsutsui et al. (2025) — JCS/JHFS Heart Failure Guideline; taurine Class IIb adjunctive. PMID: 40159241
49. EFSA ANS Panel (2009) — Taurine Scientific Opinion in energy drinks. EFSA-Q-2007-057
50. EFSA (2025) — Feed additive reauthorization incl. poultry/porcine 0.2%. PMID: 40708713
51. Yoshida et al. (2026) response letter — MELAS taurine efficacy methodology debate. PMID: 41945256

Reviews & Special Topics

52. Ames (2018) PNAS — Longevity vitamins & proteins. PMID: 30322941
53. Inam-U-Llah et al. (2018) Amino Acids — Taurine in diabetes review. PMID: 29492671
54. Kurtz et al. (2021) JISSN — Taurine in sports and exercise. PMID: 34039357
55. Zheng et al. (2016) JCEM — Plasma taurine + diabetes GRS + insulin sensitivity RCT analysis. PMID: 27466884
56. Seghieri & Franconi (2025) — Sex-gender gap in taurine trials. PMID: 40869416
57. Naddafha et al. (2026) Nutrients — Heat tolerance review. PMID: 41754109
58. Gavriel et al. (2025) Drug Dev Res — Reduced SLC6A6 in AD LCLs. PMID: 40631607
59. Na et al. (2024) Biomolecules — MELAS review. PMID: 39766231

Additional Resources

• Cognitive Vitality (ADDF): https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Taurine_(supplement).pdf
• NIH Office of Dietary Supplements — Taurine fact sheet
• Examine.com — Taurine evidence summary
• ClinicalTrials.gov — 55+ trials; search "taurine"
• Taurine Powder 98% "Taisho" Rx package insert — rad-ar.or.jp